A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma Interventions: Drug: volrustomig Sponsors: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer & Oncology | Carcinoma | HNSCC | Research | Skin Cancer | Squamous Cell Carcinoma | Study